<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-209
Date of Submission: 2025-04-23

This report was submitted by a Pharmacist from Jimenez-Wilson Medical Center concerning patient ANON-PX-4847. The subject is a 76-year-old female with a significant medical history including atrial fibrillation, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Atorvastatin administered via the Oral route at a dosage of 362mg, initiated on 2025-01-31 for Hypercholesterolemia and discontinued on 2025-04-20.

On approximately 2025-03-18, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Angioedema, Anaphylaxis. The Headache was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. The Angioedema was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2025-209
report_date: '2025-04-23'
patient_details:
  patient_id: ANON-PX-4847
  gender: Female
  relevant_history:
  - atrial fibrillation
  - chronic kidney disease
  age_at_reaction: 76
suspected_drugs:
- drug_name: Atorvastatin
  dosage: 362mg
  route_of_administration: Oral
  start_date: '2025-01-31'
  indication_for_use: Hypercholesterolemia
  end_date: '2025-04-20'
adverse_reactions:
- symptom_name: Headache
  onset_date: '2025-03-18'
  severity: Life-threatening
  outcome: Recovering
  intervention_required: true
- symptom_name: Angioedema
  onset_date: '2025-03-18'
  severity: Moderate
  outcome: Fatal
  intervention_required: false
- symptom_name: Anaphylaxis
  onset_date: '2025-03-18'
  severity: Mild
  outcome: Unknown
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Rechallenge not performed
reporting_facility: Jimenez-Wilson Medical Center
reporter_type: Pharmacist
